Supplementary Documents [IFRS]

Financial results for the fiscal year 2015 (FY2015)

Astellas Pharma Inc.

- FY2015 Financial Results
  - For the year ended March 31, 2016
  - Three months ended March 31, 2016
- Pipeline list

Cautionary statement regarding forward-looking information
This material includes forward-looking statements based on assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties.
Actual financial results may differ materially depending on a number of factors including adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regulatory developments, delays in new product launch, pricing and product initiatives of competitors, the inability of the company to market existing and new products effectively, interruptions in production, infringements of the company's intellectual property rights and the adverse outcome of material litigation.
This material contains information on pharmaceuticals (including compounds under development), but this information is not intended to make any representations or advertisements regarding the efficacy or effectiveness of these preparations, promote unapproved uses in any fashion nor provide medical advice of any kind.

[For the year ended March 31, 2016]

1. Consolidated Results (Full Basis)

Unit: B¥

	FY14 Full Year	FY15 Full Year	Change	Change (%)
Sales	1,247.3	1,372.7	125.4	10.1%
Cost of sales	333.2	335.6	2.4	0.7%
Ratio to Sales	26.7%	24.4%		
Gross profit	914.1	1,037.1	123.0	13.5%
SG&A expenses	452.5	500.4	47.8	10.6%
Ratio to Sales	36.3%	36.5%		
Advertising and Sales Promotion	138.5	169.1	30.7	22.1%
Personnel expenses	178.1	186.1	8.0	4.5%
Other	136.0	145.1	9.2	6.7%
R&D expenses	206.6	225.7	19.1	9.2%
Ratio to Sales	16.6%	16.4%		
Amortisation of intangible assets	38.7	42.4	3.7	9.6%
Share of profits/losses of associates and joint ventures	0.2	-1.2	-1.5	-
Other income	12.5	1.7	-10.8	-86.5%
Gain on sales of property, plant and equipment	1.4	0.3	-1.1	-78.5%
Other expense	43.3	20.2	-23.2	-53.5%
Loss on sales and disposal of property, plant and equipment	1.2	0.7	-0.5	-38.7%
Impairment losses	10.3	9.5	-0.8	-7.8%
Restructuring costs	11.5	-	-11.5	-
Net foreign exchange losses	3.6	7.0	3.4	96.1%
Litigation costs	16.2	2.3	-13.9	-85.7%
Operating profit	185.7	249.0	63.3	34.1%
Ratio to Sales	14.9%	18.1%		
Finance income	7.1	14.4	7.3	103.1%
Gain on sales of available-for-sale financial assets	5.1	12.3	7.1	138.4%
Finance expense	3.1	1.6	-1.5	-47.1%
Impairment losses for available-for-sale financial assets	2.6	0.4	-2.2	-85.8%
Profit before tax	189.7	261.8	72.1	38.0%
Ratio to Sales	15.2%	19.1%		
Income tax expense	53.8	68.1	14.3	26.5%
Profit for the year	135.9	193.7	57.8	42.6%
Ratio to Sales	10.9%	14.1%		
Comprehensive income	169.5	130.9	-38.6	-22.8%

Unit: B¥

	FY15 Revised Forecasts
Sales	1,384.0
Cost of sales	
Ratio to Sales	
Gross profit	
SG&A expenses	
Ratio to Sales	
Advertising and Sales Promotion	
Personnel expenses	
Other	
R&D expenses	238.0
Ratio to Sales	17.2%
Amortisation of intangible assets	
Share of profits/losses of associates and joint ventures	
Other income	
Gain on sales of property, plant and equipment	
Other expense	
Loss on sales and disposal of property, plant and equipment	
Impairment losses	
Restructuring costs	
Net foreign exchange losses	
Litigation costs	
Operating profit	229.0
Ratio to Sales	16.5%
Finance income	
Gain on sales of available-for-sale financial assets	
Finance expense	
Impairment losses for available-for-sale financial assets	
Profit before tax	242.0
Ratio to Sales	17.5%
Income tax expense	
Profit for the year	172.0
Ratio to Sales	12.4%

Forecasts

	FY16 Full Year	Change from FY15 Change (%)
Sales	1,350.0	-1.7%
Cost of sales		
Ratio to Sales		
Gross profit		
SG&A expenses		
Ratio to Sales		
Advertising and Sales Promotion		
Personnel expenses		
Other		
R&D expenses	231.0	2.4%
Ratio to Sales	17.1%	
Amortisation of intangible assets		
Share of profits/losses of associates and joint ventures		
Other income		
Gain on sales of property, plant and equipment		
Other expense		
Loss on sales and disposal of property, plant and equipment		
Impairment losses		
Restructuring costs		
Net foreign exchange losses		
Litigation costs		
Operating profit	267.0	7.2%
Ratio to Sales	19.8%	
Finance income		
Gain on sales of available-for-sale financial assets		
Finance expense		
Impairment losses for available-for-sale financial assets		
Profit before tax	268.0	2.4%
Ratio to Sales	19.9%	
Income tax expense		
Profit for the year	197.0	1.7%
Ratio to Sales	14.6%	

2. Consolidated Results (Core Basis)

Unit: B¥

	FY14 Full Year	FY15 Full Year	Change	Change (%)	FY15 Revised Forecasts	FY16 Full Year	Change from FY15 (%)
Sales	1,247.3	1,372.7	125.4	10.1%	1,384.0	1,350.0	-1.7%
Cost of sales	333.2	335.6	2.4	0.7%			
Ratio to Sales	26.7%	24.4%					
Gross profit	914.1	1,037.1	123.0	13.5%			
SG&A expenses	452.5	500.4	47.8	10.6%			
Ratio to Sales	36.3%	36.5%					
Advertising and Sales Promotion	138.5	169.1	30.7	22.1%			
Personnel expenses	178.1	186.1	8.0	4.5%			
Other	136.0	145.1	9.2	6.7%			
R&D expenses	206.6	225.7	19.1	9.2%	238.0	231.0	2.4%
Ratio to Sales	16.6%	16.4%			17.2%	17.1%	
Amortisation of intangible assets	38.7	42.4	3.7	9.6%			
Share of profits/losses of associates and joint ventures	0.2	-1.2	-1.5	-			
Operating profit	216.5	267.5	51.0	23.5%	244.0	270.0	1.0%
Ratio to Sales	17.4%	19.5%			17.6%	20.0%	
Finance income	1.9	2.1	0.2	9.5%			
Finance expense	0.4	1.0	0.6	158.9%			
Profit before Tax	218.1	268.6	50.5	23.2%			
Ratio to Sales	17.5%	19.6%					
Income tax expense	64.8	69.8	5.0	7.7%			
Profit for the year	153.2	198.8	45.6	29.7%	175.0	199.0	0.1%
Ratio to Sales	12.3%	14.5%			12.6%	14.7%	

3. Exchange Rate

Unit: yen

	FY14 Ave.	FY15 Ave.	FY14 End	FY15 End	FY15 Revised Forecasts	FY16 Full Year
USD/Yen	110	120	120	113	121	110
EUR/Yen	139	133	130	128	133	125

* Exchange rate fluctuations had positive impact by 26.1 billion yen on sales and positive impact by 9.5 billion yen on Core operating profit in FY2015

4. Reconciliation of Full Basis to Core Basis

Unit: B¥

	FY14			FY15		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Sales	**1,247.3**	**-**	**1,247.3**	**1,372.7**	**-**	**1,372.7**
Cost of sales	333.2	-	333.2	335.6	-	335.6
Gross profit	**914.1**	**-**	**914.1**	**1,037.1**	**-**	**1,037.1**
SG&A expenses	452.5	-	452.5	500.4	-	500.4
R&D expenses	206.6	-	206.6	225.7	-	225.7
Amortisation of intangible assets	38.7	-	38.7	42.4	-	42.4
Share of profits/losses of associates and joint ventures	0.2	-	0.2	-1.2	-	-1.2
Other income *1	12.5	-12.5	-	1.7	-1.7	-
Other expense *1	43.3	-43.3	-	20.2	-20.2	-
Operating profit	**185.7**	**30.8**	**216.5**	**249.0**	**18.5**	**267.5**
Finance income *2	7.1	-5.1	1.9	14.4	-12.3	2.1
Finance expense *2	3.1	-2.7	0.4	1.6	-0.6	1.0
Profit before tax	**189.7**	**28.4**	**218.1**	**261.8**	**6.8**	**268.6**
Income tax expense	53.8	11.0	64.8	68.1	1.7	69.8
Profit for the year	**135.9**	**17.4**	**153.2**	**193.7**	**5.1**	**198.8**

*1. “Other income” and “Other expense” are excluded from Core results.
“Other income” and “Other expense” include gain/loss on sale and disposal of property, plant and equipment, impairment losses, loss on the restructuring, litigation costs and foreign exchange gains/losses, etc.

*2. Gain/loss on sale of available-for-sale (“AFS”) and impairment losses of AFS included in “Finance income” and “Finance expense” are excluded from Core results as non-core items.

5. Sales by Region

Unit: B¥

		FY14 Full Year	FY15 Full Year	Change	Change (%)	FY15 Revised Forecasts (Unit: B¥)	Forecasts FY16 Full Year	Change from FY15 (%)
Sales		1,247.3	1,372.7	125.4	10.1%	1,384.0	1,350.0	-1.7%
	Japan	498.7	497.2	-1.5	-0.3%	504.4	480.8	-3.3%
	Ratio to Sales	40.0%	36.2%			36.4%	35.6%	
	Americas	361.0	455.1	94.1	26.1%	452.1	441.2	-3.1%
	Ratio to Sales	28.9%	33.2%			32.7%	32.7%	
	EMEA	313.3	329.3	16.0	5.1%	335.0	339.6	3.1%
	Ratio to Sales	25.1%	24.0%			24.2%	25.2%	
	Asia and Oceania	74.2	91.1	16.9	22.8%	92.5	88.3	-3.1%
	Ratio to Sales	5.9%	6.6%			6.7%	6.5%	

- Calculated according to locations of sellers.
- EMEA: Europe, Middle East and Africa

6. Per Share Information

	FY14 Full Year	FY15 Full Year	FY15 Revised Forecasts	Forecasts FY16 Full Year
The number of shares issued (thousand)	2,259,823	2,221,823		
Treasury Shares (thousand)	66,681	96,844		
The number of shares issued after deducting Treasury Shares (thousand)	2,193,141	2,124,978		
Earnings per share (yen)	61.50	89.75	79.37	92.71
Earnings per share (yen) core base	69.37	92.12	80.76	93.65
Dividend per share (yen)	30	32	32	34
Return on Equity (%)	10.5%	15.0%		
Dividend on Earnings (%)	5.1%	5.4%		

7. Addition to Property, Plant and Equipment

Depreciation/Amortisation

Unit: B¥

		FY14 Full Year	FY15 Full Year	Change	Change (%)	FY15 Revised Forecasts (Unit: B¥)	Forecasts FY16 Full Year	Change from FY15 (%)
Addition to Property, Plant and Equipment								
	Consolidated	30.6	34.0	3.4	11.2%	35.0	32.0	-6.0%
Depreciation (PP&E)								
	Consolidated	21.3	21.0	-0.4	-1.7%	22.5	22.0	5.0%
Amortisation (Intangible Assets) *								
	Consolidated	44.2	48.2	4.1	9.2%	50.0	43.5	-9.8%

* Amortisation (Intangible Assets): Including amortisation of software, etc.

8. Sales of major products

1) Sales of global products

Unit: B¥

	FY14 Full Year	FY15 Full Year	Change	Change (%)
XTANDI	137.2	252.1	114.9	83.7%
US	85.7	148.4	62.7	73.2%
ex-US	51.5	103.7	52.2	101.3%
Japan	14.9	26.2	11.3	76.1%
Americas (ex-US)	2.6	4.5	1.9	71.5%
EMEA	33.4	70.7	37.2	111.5%
Asia and Oceania	0.6	2.4	1.8	290.5%
Eligard	19.0	17.6	-1.4	-7.3%
EMEA	18.9	17.4	-1.5	-8.0%
Asia and Oceania	0.1	0.2	0.1	228.4%
Vesicare	135.2	135.6	0.4	0.3%
Japan	25.6	26.5	0.9	3.5%
Americas	61.4	63.7	2.3	3.7%
EMEA	42.3	39.8	-2.4	-5.8%
Asia and Oceania	5.3	5.3	0.0	0.1%
Betanis/Myrbetriq/Betmiga	53.1	81.7	28.6	53.8%
Japan	14.8	21.2	6.4	43.5%
Americas	27.9	45.7	17.8	63.7%
EMEA	10.3	13.4	3.1	29.9%
Asia and Oceania	0.2	1.4	1.3	772.7%
Harnal/Omnic	56.0	53.4	-2.6	-4.6%
Sales by Astellas	51.9	50.4	-1.5	-2.8%
Japan	15.0	12.7	-2.3	-15.6%
EMEA	18.0	15.4	-2.5	-14.1%
Asia and Oceania	18.3	21.5	3.2	17.7%
Bulk and Royalties	4.1	3.0	-1.1	-26.7%
Prograf	194.7	203.6	8.8	4.5%
Sales by Astellas	190.9	200.7	9.8	5.2%
Japan (Including Graceptor)	48.1	49.8	1.6	3.4%
Americas	33.0	34.6	1.6	4.8%
EMEA	77.7	77.9	0.2	0.2%
Advagraf	28.7	31.1	2.4	8.2%
Asia and Oceania	32.0	38.4	6.4	20.2%
Exports to third parties	3.8	2.8	-1.0	-25.7%
Funguard/Mycamine	38.8	41.6	2.9	7.4%
Japan	11.8	11.7	-0.1	-1.1%
Americas	12.4	13.0	0.7	5.5%
EMEA	10.2	11.2	1.0	9.6%
Asia and Oceania	4.4	5.7	1.3	30.3%
Protopic	21.7	15.6	-6.0	-27.8%
Americas	10.3	3.1	-7.2	-69.6%
EMEA	7.8	7.7	-0.1	-1.0%
Asia and Oceania	3.4	4.6	1.1	32.9%

Unit: B¥

	FY15 Revised Forecasts
XTANDI	253.3
US	147.6
ex-US	105.8
Japan	28.0
Americas (ex-US)	4.3
EMEA	71.1
Asia and Oceania	2.3
Eligard	18.2
EMEA	18.0
Asia and Oceania	0.2
Vesicare	133.4
Japan	27.0
Americas	62.4
EMEA	38.2
Asia and Oceania	5.6
Betanis/Myrbetriq/Betmiga	81.9
Japan	22.1
Americas	44.3
EMEA	14.6
Asia and Oceania	0.9
Harnal/Omnic	56.0
Sales by Astellas	52.0
Japan	12.8
EMEA	16.7
Asia and Oceania	21.8
Bulk and Royalties	4.0
Prograf	202.5
Sales by Astellas	199.8
Japan (Including Graceptor)	50.7
Americas	33.3
EMEA	77.3
Advagraf	
Asia and Oceania	38.5
Exports to third parties	2.7
Funguard/Mycamine	42.4
Japan	12.1
Americas	12.9
EMEA	11.7
Asia and Oceania	5.6
Protopic	14.9
Americas	2.9
EMEA	7.0
Asia and Oceania	4.8

Forecasts

	FY16 Full Year	Change from FY15 (%)
XTANDI	295.9	17.4%
US	163.7	10.3%
ex-US	132.2	27.5%
Japan	25.7	-2.0%
Americas (ex-US)	6.1	36.3%
EMEA	95.9	35.8%
Asia and Oceania	4.5	88.2%
Eligard	17.6	0.1%
EMEA	17.3	-0.7%
Asia and Oceania	0.3	67.7%
Vesicare	119.1	-12.2%
Japan	27.2	2.7%
Americas	53.7	-15.7%
EMEA	32.4	-18.7%
Asia and Oceania	5.4	2.8%
Betanis/Myrbetriq/Betmiga	100.4	22.8%
Japan	27.4	29.0%
Americas	51.9	13.7%
EMEA	18.3	36.4%
Asia and Oceania	2.8	94.5%
Harnal/Omnic	46.4	-13.1%
Sales by Astellas	44.2	-12.3%
Japan	9.4	-25.7%
EMEA	13.7	-11.5%
Asia and Oceania	20.5	-4.6%
Bulk and Royalties	2.2	-26.8%
Prograf	187.9	-7.7%
Sales by Astellas	185.4	-7.6%
Japan (Including Graceptor)	47.8	-3.9%
Americas	26.9	-22.3%
EMEA	73.6	-5.5%
Advagraf		
Asia and Oceania	37.1	-3.5%
Exports to third parties	2.5	-13.1%
Funguard/Mycamine	40.4	-3.0%
Japan	11.5	-1.7%
Americas	11.8	-9.8%
EMEA	11.2	-0.4%
Asia and Oceania	6.0	4.7%
Protopic		
Americas		
EMEA		
Asia and Oceania		

- Sales of products in Japan are shown in a gross sales basis.
- EMEA: Europe, Middle East and Africa
- Astellas' global dermatology business including Protopic was transferred to LEO Pharma A/S on April 1, 2016.

2) Sales of products in Japan

Unit: B¥

<Global products>	FY14 Full Year	FY15 Full Year	Change	Change (%)	Unit: B¥ FY15 Revised Forecasts	Forecasts FY16 Full Year	Change from FY15 Change (%)
XTANDI	14.9	26.2	11.3	76.1%	28.0	25.7	-2.0%
Vesicare	25.6	26.5	0.9	3.5%	27.0	27.2	2.7%
Betanis	14.8	21.2	6.4	43.5%	22.1	27.4	29.0%
Harnal	15.0	12.7	-2.3	-15.6%	12.8	9.4	-25.7%
Prograf （Including Graceptor）	48.1	49.8	1.6	3.4%	50.7	47.8	-3.9%
Funguard	11.8	11.7	-0.1	-1.1%	12.1	11.5	-1.7%
<Local products in Japan>							
Micardis [Family]	95.7	97.2	1.4	1.5%	98.5	90.8	-6.5%
Micombi	10.7	10.1	-0.6	-5.5%			
Micamlo	23.8	26.0	2.2	9.1%			
Celecox	41.8	46.6	4.8	11.5%	46.9	50.4	8.2%
Symbicort	33.0	37.4	4.4	13.3%	37.0	41.1	9.9%
Bonoteo	13.0	14.1	1.1	8.6%	14.5	15.1	7.1%
Geninax	10.4	10.8	0.5	4.6%	10.6	10.2	-6.1%
Vaccines	38.8	41.1	2.3	5.9%	40.0	25.9	-37.1%
Argamate	5.9	6.2	0.2	3.5%	6.2	6.1	-1.4%
Kiklin	1.5	1.6	0.1	5.2%	1.7	2.0	28.7%
Gonax	3.4	3.9	0.5	14.3%	4.0	4.6	17.6%
Cimzia	5.0	6.6	1.5	30.2%	6.7	9.6	47.1%
Suglat	4.1	7.3	3.2	77.8%	8.3	12.5	71.1%
Lipitor*	36.7	30.9	-5.8	-15.9%	30.5	22.4	-27.4%
Myslee	19.4	17.9	-1.4	-7.3%	17.6	14.6	-18.5%
Gaster	18.0	14.7	-3.3	-18.5%	14.8	10.5	-28.3%
Seroquel	12.6	10.5	-2.1	-16.9%	10.7	7.2	-31.3%
Total Rx Sales In Japanese market	481.7	483.0	1.2	0.3%	489.8	456.6	-5.5%

* Transfer of Distribution for Caduet to Pfizer on April 1, 2015. Sales in FY2014 exclude sales of Caduet.

- Sales of products in Japan are shown in a gross sales basis.

3) Sales of products in Americas and EMEA

Unit: B¥

		FY14 Full Year	FY15 Full Year	Change	Change (%)	Unit: B¥ FY15 Revised Forecasts	Forecasts FY16 Full Year	Change from FY15 Change (%)
Tarceva		48.9	46.8	-2.1	-4.3%			
	(US)	33.5	33.8	0.3	0.8%			
	(ex-US)	15.3	13.0	-2.4	-15.4%			
Scan*	(Americas)	66.3	76.2	9.9	14.9%	77.8	70.1	-8.0%
AmBisome	(Americas)	9.0	10.9	1.9	21.5%	10.4	9.8	-10.3%
CRESEMBA	(Americas)	-	2.6	2.6	-		5.0	91.5%
Qutenza	(EMEA)	1.9	2.1	0.3	15.2%			
DIFICLIR	(EMEA)	2.0	2.6	0.6	29.0%			

* Adenoscan + Lexiscan

- EMEA: Europe, Middle East and Africa

4) Sales in Americas and EMEA (Local currency)

Unit: M$

Americas	FY14 Full Year	FY15 Full Year	Change	Change (%)	Unit:M$ FY15 Revised Forecasts	Forecasts FY16 Full Year	Change from FY15 Change (%)
Sales	3,284	3,788	504	15.4%	3,739	4,011	5.9%
XTANDI	803	1,272	469	58.4%	1,256	1,544	21.3%
US	779	1,235	456	58.4%	1,220	1,488	20.5%
Americas (ex-US)	24	37	14	57.0%	36	56	48.9%
Tarceva	444	389	-55	-12.4%			
US	305	281	-24	-7.7%			
ex-US	139	108	-31	-22.6%			
VESIcare	559	530	-28	-5.1%	516	488	-8.0%
Myrbetriq	254	380	126	49.8%	367	472	24.2%
Prograf	301	288	-12	-4.1%	275	245	-15.1%
Scan[*1]	603	634	31	5.1%	643	637	0.4%
MYCAMINE	112	109	-4	-3.5%	107	107	-1.5%
AmBisome	82	91	9	11.2%	86	89	-2.1%
CRESEMBA	-	22	22	-		45	109.1%
Protopic[*2]	94	26	-68	-72.2%	24		

[*1] Adenoscan + Lexiscan

[*2] Astellas' global dermatology business including Protopic was transferred to LEO Pharma A/S on April 1, 2016.

Unit: M€

EMEA	FY14 Full Year	FY15 Full Year	Change	Change (%)	Unit:M€ FY15 Revised Forecasts	Forecasts FY16 Full Year	Change from FY15 Change (%)
Sales	2,258	2,484	226	10.0%	2,528	2,717	9.4%
XTANDI	241	533	292	121.3%	537	767	44.0%
Eligard	136	131	-5	-3.7%	136	138	5.4%
Vesicare	305	300	-4	-1.4%	288	259	-13.7%
BETMIGA	74	101	27	36.0%	110	146	44.7%
Omnic	159	139	-20	-12.6%	157	127	-8.8%
Sales by Astellas	130	116	-13	-10.1%	126	109	-6.1%
Bulk and Royalties	30	23	-7	-23.3%	30	18	-22.3%
Prograf	588	609	21	3.6%	603	609	-0.1%
Sales by Astellas	560	588	27	4.9%	583	589	0.2%
Advagraf	207	234	27	13.3%			
Exports to third parties	28	21	-6	-22.3%	20	20	-7.9%
MYCAMINE	74	85	11	14.7%	88	90	5.7%
Protopic*	56	58	2	3.6%	53		
Qutenza	13	16	3	20.6%			
DIFICLIR	14	20	5	35.0%			

* Astellas' global dermatology business including Protopic was transferred to LEO Pharma A/S on April 1, 2016.

- EMEA: Europe, Middle East and Africa

9.Consolidated statements of financial position

Unit: B¥

			31-Mar-15	31-Mar-16	
			Amount	Amount	Change
Assets			**1,793.6**	**1,799.3**	**5.8**
	Non-current assets		**827.6**	**901.8**	**74.2**
		Property, plant and equipment	202.9	201.0	-1.9
		Goodwill	136.3	150.7	14.3
		Other intangible assets	295.8	339.2	43.4
		Trade and other receivables	15.6	24.1	8.5
		Investments in associates and joint ventures	2.0	2.4	0.4
		Deferred tax assets	51.2	80.3	29.1
		Other financial assets	110.1	89.4	-20.7
		Other non-current assets	13.7	14.8	1.1
	Current assets		**966.0**	**897.5**	**-68.4**
		Inventories	156.9	161.7	4.8
		Trade and other receivables	332.9	327.6	-5.3
		Income tax receivable	6.9	16.4	9.5
		Other financial assets	59.9	14.4	-45.5
		Other current assets	12.7	17.2	4.5
		Cash and cash equivalents	396.4	360.0	-36.4
		Assets held for sale	0.1	0.2	0.1

Unit: B¥

	31-Mar-15	31-Mar-16	
	Amount	Amount	Change
Equity and Liabilities	**1,793.6**	**1,799.3**	**5.8**
Equity	**1,317.9**	**1,259.2**	**-58.7**
Equity attributable to owners of the parent	**1,317.9**	**1,259.2**	**-58.7**
Share capital	103.0	103.0	-
Capital surplus	176.8	176.9	0.1
Treasury shares	-87.0	-157.1	-70.1
Retained earnings	905.1	973.1	68.0
Other components of equity	220.0	163.4	-56.6
Liabilities	**475.7**	**540.1**	**64.5**
Non-current liabilities	**54.8**	**126.8**	**72.0**
Trade and other payables	0.1	1.6	1.5
Deferred tax liabilities	0.0	-	-0.0
Retirement benefit liabilities	30.1	39.8	9.7
Provisions	4.8	7.1	2.3
Other financial liabilities	0.6	0.7	0.1
Other non-current liabilities	19.1	77.6	58.4
Current liabilities	**420.9**	**413.4**	**-7.5**
Trade and other payables	226.6	181.6	-45.0
Income tax payable	14.1	19.3	5.2
Provisions	85.4	89.9	4.4
Other financial liabilities	1.3	1.5	0.2
Other current liabilities	93.4	121.1	27.7

10. Employees

Number of employees

	FY14 End	FY15 End
Total	17,113	17,217
Japan	7,241	7,056
Americas	2,975	3,062
EMEA	4,628	4,726
Asia and Oceania	2,269	2,373
Total Medical Representatives	6,400	6,000

- EMEA: Europe, Middle East and Africa

11. Shareholders

	FY14 End	FY15 End
Banks	30.1%	31.3%
Securities	3.4%	3.9%
Other companies	3.4%	3.4%
Foreign companies	52.7%	48.5%
Individuals and others	7.6%	8.6%
Treasury Stock*	3.0%	4.3%

* Treasury Stock does not include shares owned by the executive compensation BIP (Board Incentive Plan) trust

[Three months ended March 31, 2016]

1. Consolidated Results (Full Basis)

Unit: B¥

	FY15							
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Sales	343.7	16.4%	343.8	14.9%	378.2	5.5%	307.0	4.3%
Cost of sales	90.1	18.6%	78.3	-5.8%	102.1	1.7%	65.1	-11.7%
Ratio to Sales	26.2%		22.8%		27.0%		21.2%	
Gross profit	253.6	15.7%	265.5	22.8%	276.1	7.0%	241.9	9.6%
SG&A expenses	118.7	22.4%	121.1	15.5%	122.9	6.5%	137.7	1.8%
Ratio to Sales	34.5%		35.2%		32.5%		44.8%	
Advertising and Sales Promotion	41.6	47.7%	41.7	55.3%	41.7	9.5%	44.1	-2.7%
Personnel expenses	45.1	6.3%	46.2	7.7%	46.0	3.4%	48.8	1.1%
Other	32.0	21.4%	33.2	-5.5%	35.2	7.2%	44.7	7.4%
R&D expenses	56.0	17.5%	56.1	13.5%	53.0	3.9%	60.7	3.5%
Ratio to Sales	16.3%		16.3%		14.0%		19.8%	
Amortisation of intangible assets	10.9	22.8%	11.0	21.5%	11.2	11.5%	9.2	-13.3%
Share of profits/losses of associates and joint ventures	-0.2	-	-0.0	-	-0.2	-	-0.8	-
Other income	1.3	-53.2%	0.3	-91.0%	0.2	-78.7%	0.6	-96.0%
Gain on sales of property, plant and equipment	0.1	799.6%	0.1	-92.5%	0.1	567.0%	-0.0	-299.5%
Net foreign exchange gains	0.6	-74.3%	-	-	-	-	-	-
Other expense	7.2	-60.4%	6.9	98.4%	5.9	-74.7%	0.8	-88.8%
Loss on sales and disposal of property, plant and equipment	0.1	-54.9%	0.2	-52.3%	0.2	35.5%	0.3	-48.6%
Impairment losses	6.6	-18.7%	-	-	3.0	264.6%	-	-
Restructuring costs	-	-	-	-	-	-	-	-
Net foreign exchange losses	-	-	6.5	794.3%	1.1	-90.8%	0.0	-
Litigation costs	0.4	-11.9%	0.1	709.5%	1.6	-84.5%	0.2	-96.6%
Operating profit	61.9	22.4%	70.7	34.4%	83.0	41.8%	33.4	39.2%
Ratio to Sales	18.0%		20.6%		21.9%		10.9%	
Finance income	6.0	230.4%	7.3	-	0.4	-25.1%	0.6	-85.5%
Gain on sales of available-for-sale financial assets	5.5	540.2%	6.6	-	-	-	0.2	-94.5%
Finance expense	0.3	-86.9%	0.3	-56.6%	0.4	149.6%	0.7	376.5%
Impairment losses for available-for-sale financial assets	0.0	-98.5%	0.1	-87.8%	0.0	-	0.2	-
Profit before tax	67.7	34.6%	77.8	48.4%	83.0	40.9%	33.3	18.7%
Ratio to Sales	19.7%		22.6%		22.0%		10.8%	
Income tax expense	23.0	59.8%	19.4	6.4%	21.4	51.1%	4.2	-40.1%
Profit for the year	44.6	24.4%	58.3	70.9%	61.6	37.7%	29.1	38.0%
Ratio to Sales	13.0%		17.0%		16.3%		9.5%	
Comprehensive income	71.8	219.0%	33.0	-49.4%	61.7	-43.9%	-35.7	-26.8%

2. Consolidated Results (Core Basis)

Unit: B¥

	FY15							
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Sales	343.7	16.4%	343.8	14.9%	378.2	5.5%	307.0	4.3%
Cost of sales	90.1	18.6%	78.3	-5.8%	102.1	1.7%	65.1	-11.7%
Ratio to Sales	26.2%		22.8%		27.0%		21.2%	
Gross profit	253.6	15.7%	265.5	22.8%	276.1	7.0%	241.9	9.6%
SG&A expenses	118.7	22.4%	121.1	15.5%	122.9	6.5%	137.7	1.8%
Ratio to Sales	34.5%		35.2%		32.5%		44.8%	
Advertising and Sales Promotion	41.6	47.7%	41.7	55.3%	41.7	9.5%	44.1	-2.7%
Personnel expenses	45.1	6.3%	46.2	7.7%	46.0	3.4%	48.8	1.1%
Other	32.0	21.4%	33.2	-5.5%	35.2	7.2%	44.7	7.4%
R&D expenses	56.0	17.5%	56.1	13.5%	53.0	3.9%	60.7	3.5%
Ratio to Sales	16.3%		16.3%		14.0%		19.8%	
Amortisation of intangible assets	10.9	22.8%	11.0	21.5%	11.2	11.5%	9.2	-13.3%
Share of profits/losses of associates and joint ventures	-0.2	-	-0.0	-	-0.2	-	-0.8	-
Operating profit	67.8	2.8%	77.3	45.4%	88.7	9.5%	33.6	106.0%
Ratio to Sales	19.7%		22.5%		23.5%		10.9%	
Finance income	0.6	-43.2%	0.7	188.6%	0.5	-18.1%	0.4	127.0%
Finance expense	0.1	-20.5%	0.2	257.6%	0.3	108.4%	0.5	348.1%
Profit before Tax	68.3	2.2%	77.9	45.8%	88.9	9.1%	33.5	104.7%
Ratio to Sales	19.9%		22.6%		23.5%		10.9%	
Income tax expense	23.3	13.8%	19.0	1.1%	23.4	5.6%	4.1	20.1%
Profit for the year	45.0	-3.0%	58.9	70.0%	65.4	10.5%	29.4	127.0%
Ratio to Sales	13.1%		17.1%		17.3%		9.6%	

3. Sales by Region

Unit: B¥

		FY15							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Sales		343.7	16.4%	343.8	14.9%	378.2	5.5%	307.0	4.3%
	Japan	125.6	11.3%	121.5	-2.3%	149.7	-1.1%	100.4	-8.8%
	Ratio to Sales	36.6%		35.3%		39.6%		32.7%	
	Americas	114.8	36.9%	118.1	40.3%	115.8	15.5%	106.4	14.8%
	Ratio to Sales	33.4%		34.4%		30.6%		34.7%	
	EMEA	81.7	-0.8%	80.5	8.7%	89.1	2.6%	77.9	11.3%
	Ratio to Sales	23.8%		23.4%		23.6%		25.4%	
	Asia and Oceania	21.5	34.0%	23.7	42.4%	23.6	18.9%	22.3	3.1%
	Ratio to Sales	6.3%		6.9%		6.2%		7.3%	

- Calculated according to locations of sellers.
- EMEA: Europe, Middle East and Africa

4. Addition to Property, Plant and Equipment
Depreciation/Amortisation

Unit: B¥

		FY15							
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
Addition to Property, Plant and Equipment									
	Consolidated	12.6	273.1%	5.8	-20.9%	7.2	-44.7%	8.4	22.7%
Depreciation (PP&E)									
	Consolidated	5.0	-4.5%	5.2	-6.2%	5.2	1.6%	5.5	2.4%
Amortisation (Intangible Assets) *									
	Consolidated	12.4	21.1%	12.5	20.0%	12.7	10.5%	10.7	-11.3%

* Amortisation (Intangible Assets): Including amortisation of software, etc.

5. Sales of major products
1) Sales of global products

Unit: B¥

	FY15							
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)	OCT.-DEC. (Quarterly)	Change (%)	JAN.-MAR. (Quarterly)	Change (%)
XTANDI	59.1	152.8%	63.3	102.4%	66.4	64.8%	63.3	49.8%
US	36.2	146.7%	38.3	103.2%	38.4	48.5%	35.5	34.9%
ex-US	22.8	163.2%	25.0	101.1%	28.0	94.0%	27.8	74.5%
Japan	6.8	346.5%	6.3	53.3%	7.1	56.0%	6.0	27.9%
Americas (ex-US)	1.0	151.6%	1.2	127.0%	1.1	13.7%	1.1	63.7%
EMEA	14.6	117.3%	16.9	118.6%	19.1	120.5%	20.0	94.6%
Asia and Oceania	0.4	-	0.6	937.5%	0.7	191.7%	0.7	140.0%
Eligard	4.4	-12.3%	4.4	0.3%	4.8	-5.8%	3.9	-10.6%
EMEA	4.4	-12.9%	4.3	-0.9%	4.8	-6.7%	3.9	-11.1%
Asia and Oceania	0.0	349.7%	0.1	819.7%	0.1	231.7%	0.0	62.8%
Vesicare	35.4	7.1%	34.3	2.3%	35.1	-6.6%	30.8	-0.8%
Japan	6.8	29.6%	6.5	-0.9%	7.2	-2.9%	5.9	-6.4%
Americas	17.1	9.9%	16.2	8.1%	15.7	-8.8%	14.7	7.7%
EMEA	10.2	-7.2%	10.1	-2.7%	10.6	-7.9%	8.9	-5.0%
Asia and Oceania	1.2	7.6%	1.4	10.8%	1.4	4.1%	1.3	-17.8%
Betanis/Myrbetriq/BETMIGA	18.1	69.1%	20.0	71.7%	22.1	42.9%	21.6	40.3%
Japan	4.9	81.0%	4.9	42.9%	6.0	35.8%	5.5	28.5%
Americas	9.8	59.7%	11.6	93.2%	12.0	55.0%	12.2	53.0%
EMEA	3.3	79.7%	3.3	52.7%	3.5	9.3%	3.2	5.3%
Asia and Oceania	0.1	447.7%	0.2	396.9%	0.5	939.6%	0.7	919.2%
Harnal/Omnic	14.2	3.4%	12.9	-5.6%	14.7	-5.2%	11.6	-11.2%
Sales by Astellas	13.3	6.2%	12.4	-5.2%	13.6	-6.6%	11.1	-5.1%
Japan	3.4	-11.6%	3.3	-17.1%	3.5	-12.9%	2.5	-22.0%
EMEA	4.7	3.7%	3.3	-27.6%	4.3	-25.0%	3.1	-0.7%
Asia and Oceania	5.0	25.5%	5.6	26.3%	5.7	20.2%	5.2	2.0%
Bulk and Royalties	0.9	-25.4%	0.5	-13.1%	1.1	17.8%	0.5	-63.2%
Prograf	50.4	7.1%	54.2	12.6%	52.9	0.5%	46.1	-1.7%
Sales by Astellas	49.9	8.0%	53.2	12.6%	52.1	0.4%	45.6	-0.1%
Japan (Including Graceptor)	12.7	11.0%	12.7	3.7%	13.6	0.3%	10.7	-1.2%
Americas	8.4	-4.5%	9.7	19.4%	8.8	1.6%	7.7	3.6%
EMEA	19.6	5.2%	20.5	4.0%	20.1	-4.6%	17.7	-3.4%
Advagraf	7.5	13.8%	8.3	12.9%	8.1	4.1%	7.1	2.5%
Asia and Oceania	9.2	25.7%	10.3	43.7%	9.5	11.8%	9.4	4.9%
Exports to third parties	0.5	-41.3%	1.0	13.1%	0.8	3.2%	0.5	-59.3%
Funguard/MYCAMINE	10.3	16.3%	10.8	12.0%	10.9	-4.3%	9.7	8.4%
Japan	2.9	16.5%	3.1	-2.5%	3.2	-11.3%	2.4	-2.2%
Americas	3.3	15.5%	3.4	20.9%	3.3	-5.9%	3.0	-4.4%
EMEA	2.8	6.5%	2.8	14.0%	2.8	-8.2%	2.8	35.3%
Asia and Oceania	1.3	49.2%	1.4	26.5%	1.5	34.4%	1.5	17.4%
Protopic	4.2	-30.5%	3.7	-38.7%	4.2	-29.3%	3.6	-3.5%
Americas	1.0	-67.2%	0.9	-72.7%	0.9	-71.8%	0.3	-54.5%
EMEA	1.8	-13.4%	1.5	-17.0%	2.3	24.9%	2.1	1.6%
Asia and Oceania	1.3	66.7%	1.3	46.1%	0.9	3.3%	1.1	20.9%

- Sales of products in Japan are shown in a gross sales basis.
- EMEA: Europe, Middle East and Africa

2) Sales of products in Japan

Unit: B¥

	FY15							
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
<Global products>	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
XTANDI	6.8	346.5%	6.3	53.3%	7.1	56.0%	6.0	27.9%
Vesicare	6.8	29.6%	6.5	-0.9%	7.2	-2.9%	5.9	-6.4%
Betanis	4.9	81.0%	4.9	42.9%	6.0	35.8%	5.5	28.5%
Harnal	3.4	-11.6%	3.3	-17.1%	3.5	-12.9%	2.5	-22.0%
Prograf （Including Graceptor）	12.7	11.0%	12.7	3.7%	13.6	0.3%	10.7	-1.2%
Funguard	2.9	16.5%	3.1	-2.5%	3.2	-11.3%	2.4	-2.2%
<Local products in Japan>								
Micardis [Family]	24.8	6.3%	23.7	-0.3%	28.4	1.5%	20.2	-2.0%
Micombi	2.7	-3.0%	2.5	-7.5%	2.9	-3.8%	2.1	-8.6%
Micamlo	6.5	14.5%	6.2	8.1%	7.6	9.3%	5.7	4.4%
Celecox	11.8	41.4%	11.6	3.0%	12.7	6.1%	10.4	2.6%
Symbicort	9.0	44.2%	8.5	3.5%	11.3	7.8%	8.5	6.5%
Bonoteo	3.7	39.8%	3.4	-0.9%	3.9	5.3%	3.1	-2.9%
Geninax	2.8	20.9%	2.0	-2.5%	3.8	0.7%	2.2	0.6%
Vaccines	6.6	24.6%	7.4	1.1%	24.6	17.8%	2.5	-52.7%
Argamate	1.5	6.5%	1.5	2.9%	1.7	4.1%	1.4	0.4%
Kiklin	0.4	23.2%	0.4	3.0%	0.4	0.8%	0.3	-3.7%
Gonax	0.9	26.1%	1.0	11.6%	1.0	8.9%	0.9	12.6%
Cimzia	1.6	40.1%	1.6	29.9%	1.8	27.9%	1.5	24.0%
Suglat	2.0	-18.2%	1.4	-	2.0	187.3%	1.8	118.6%
Lipitor*	8.3	-13.1%	7.9	-18.6%	8.5	-12.6%	6.1	-20.4%
Myslee	4.7	-3.6%	4.6	-8.5%	5.0	-5.1%	3.7	-12.9%
Gaster	3.9	-17.4%	3.8	-19.8%	4.0	-14.8%	2.9	-22.7%
Seroquel	3.0	-13.4%	2.7	-15.3%	2.8	-17.6%	2.0	-22.5%
Total Rx Sales In Japanese market	122.2	12.1%	117.8	-2.3%	146.1	0.3%	96.8	-9.0%

* Transfer of Distribution for Caduet to Pfizer on April 1, 2015.

- Sales of products in Japan are shown in a gross sales basis.

3) Sales of products in Americas and EMEA

Unit: B¥

	FY15							
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Tarceva	13.1	-3.2%	12.4	11.1%	11.7	-3.9%	9.5	-20.2%
(US)	9.7	0.5%	8.9	17.4%	8.5	5.5%	6.7	-18.8%
(ex-US)	3.4	-12.3%	3.5	-2.4%	3.2	-22.2%	2.8	-23.5%
Scan* (Americas)	20.8	25.1%	19.8	27.1%	18.2	6.4%	17.4	2.4%
AmBisome (Americas)	2.8	47.7%	2.7	19.5%	2.7	14.1%	2.7	10.4%
CRESEMBA (Americas)	0.3	-	0.6	-	0.9	-	0.9	-
Qutenza (EMEA)	0.5	16.3%	0.5	15.6%	0.6	7.9%	0.6	21.7%
DIFICLIR (EMEA)	0.6	34.7%	0.7	37.1%	0.6	25.5%	0.6	19.8%

* Adenoscan + Lexiscan

- EMEA: Europe, Middle East and Africa

4) Sales in Americas and EMEA (Local currency)

Unit:M$

	FY15							
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
Americas	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Sales	946	15.2%	966	19.3%	953	8.3%	923	19.3%
XTANDI	307	107.8%	323	73.1%	325	36.0%	317	38.1%
US	298	107.6%	313	72.5%	316	37.2%	308	37.3%
Americas (ex-US)	9	111.8%	10	92.7%	9	3.7%	10	69.3%
Tarceva	108	-18.5%	101	-5.4%	97	-8.6%	83	-15.9%
US	80	-15.4%	73	0.0%	70	0.8%	58	-14.2%
ex-US	28	-26.1%	28	-16.9%	27	-26.7%	25	-19.5%
VESIcare	141	-7.5%	133	-8.0%	129	-14.1%	127	14.2%
Myrbetriq	81	34.4%	95	64.4%	99	44.7%	105	56.1%
Prograf	69	-19.6%	80	1.6%	73	-3.7%	67	9.9%
Scan*	171	5.3%	162	8.1%	150	0.7%	151	6.6%
MYCAMINE	27	-2.8%	28	2.8%	27	-12.0%	26	-0.5%
AmBisome	23	24.3%	22	1.4%	22	7.4%	23	13.7%
CRESEMBA	2	-	5	-	7	-	7	-
Protopic	8	-72.4%	8	-76.8%	7	-73.1%	3	-19.8%

* Adenoscan + Lexiscan

Unit:M€

	FY15							
	APR.-JUN.	Change	JUL.-SEP.	Change	OCT.-DEC.	Change	JAN.-MAR.	Change
EMEA	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)	(Quarterly)	(%)
Sales	609	3.5%	592	10.0%	670	10.2%	613	17.0%
XTANDI	109	126.9%	125	121.9%	144	136.1%	156	105.5%
Eligard	33	-9.1%	32	0.3%	36	0.2%	31	-6.0%
Vesicare	76	-3.1%	75	-1.4%	80	-1.0%	70	0.1%
BETMIGA	25	87.7%	25	54.9%	26	16.7%	25	12.0%
Omnic	42	1.8%	28	-25.2%	40	-13.4%	29	-14.9%
Sales by Astellas	35	8.2%	24	-26.9%	32	-19.6%	25	4.0%
Bulk and Royalties	7	-22.1%	4	-13.0%	8	26.5%	4	-59.8%
Prograf	150	7.6%	158	5.9%	157	2.8%	144	-1.7%
Sales by Astellas	146	9.8%	151	5.5%	151	2.5%	140	2.0%
Advagraf	56	18.8%	61	14.6%	61	11.8%	56	8.4%
Exports to third parties	4	-38.8%	7	15.0%	6	11.4%	4	-55.8%
MYCAMINE	21	11.2%	20	15.4%	21	-1.6%	22	41.2%
Protopic	14	-9.5%	11	-16.2%	17	34.1%	16	6.9%
Qutenza	4	21.5%	3	16.9%	4	15.6%	5	27.8%
DIFICLIR	5	40.7%	5	39.0%	5	35.0%	5	26.6%

- EMEA: Europe, Middle East and Africa

R&D Pipeline (As of May 2016)

Underlined items indicate for changes from the previous announcement on January 29, 2016.

1. Global Development

(1) Filed

*Compounds with "In-house" in this column include ones discovered by collaborative research. (The same applicable hereafter.)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor*	Remarks
YM905 solifenacin	Muscarine M_3 receptor antagonist	Overactive bladder in pediatric patients of 5-18 years	Europe Filed (Sept. 2015)	Oral	In-house	New indication (pediatric)
MDV3100 enzalutamide	Androgen receptor inhibitor	Metastatic castration-resistant prostate cancer (Tablet)	US Filed (Feb. 2016) Europe Filed (Mar. 2016)	Oral	Medivation	New formulation

(2) Phase-lll / Phase-ll (1/4)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
MDV3100 enzalutamide	Androgen receptor inhibitor	Non-metastatic castration-resistant prostate cancer, Prostate cancer in patients with non-metastatic biochemical recurrence	US/Europe/Asia Phase-III	Oral	Medivation	New indication
		Metastatic hormone-sensitive prostate cancer	US/Europe/Japan/Asia Phase-III			New indication
		Breast cancer	US/Europe Phase-II			New indication
		Hepatocellular carcinoma	US/Europe/Asia Phase-II			New indication

(2) Phase-Ⅲ / Phase-Ⅱ (2/4)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
ASP0113 (VCL-CB01)	DNA vaccine for cytomegalovirus	Cytomegalovirus reactivation in hematopoietic cell transplant recipients	US/Europe/Japan Phase-III	Injection	Vical	
		Cytomegalovirus infection or reactivation in solid organ transplant recipients	US/Europe Phase-II			
YM905 solifenacin	Muscarine M_3 receptor antagonist	Neurogenic detrusor overactivity in pediatric patients	US/Europe Phase-III	Oral	In-house	New indication (pediatric)
EB178 solifenacin/ mirabegron	Concomitant use of solifenacin and mirabegron	Urinary frequency, urinary incontinence or urgency associated with overactive bladder	US/Europe/Asia Phase-III	Oral	In-house	
fidaxomicin	Macrocyclic antibiotic	Infectious enteritis (bacterial target: *Clostridium difficile*)	Japan Phase-III	Oral	Merck	
		Clostridium difficile infection in pediatric patients	Europe Phase-III			New indication (pediatric)
ASP015K	JAK inhibitor	Rheumatoid arthritis	Japan/Asia Phase-III US/Europe Phase-II	Oral	In-house	
ASP1517 (FG-4592) roxadustat	HIF stabilizer	Anemia associated with chronic kidney disease in patients not on dialysis and on dialysis	Europe Phase-III Japan Phase-III	Oral	FibroGen	

(2) Phase-lll / Phase-ll (3/4)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
ASP2215 gilteritinib	FLT3/AXL inhibitor	Acute myeloid leukemia	US/Europe/Japan/Asia Phase-III	Oral	In-house	
		Non-small cell lung cancer	US/Japan/Asia Phase-I			
ASP8273	Mutant-selective irreversible EGFR inhibitor	Non-small cell lung cancer	US/Europe/Japan/Asia Phase-III	Oral	In-house	
YM178 mirabegron	Beta 3 receptor agonist	Neurogenic detrusor overactivity in pediatric patients	Europe Phase-III	Oral	In-house	New indication (pediatric)
YM311 (FG-2216)	HIF stabilizer	Renal anemia	Europe Phase-II Japan Phase-I	Oral	FibroGen	
ASKP1240	Anti-CD40 monoclonal antibody	Prevention of organ transplant rejection	US Phase-II Japan Phase-I	Injection	Kyowa Hakko Kirin	
ASP1707	GnRH antagonist	Endometriosis	Europe/Japan Phase-II	Oral	In-house	
ASP8232	VAP-1 inhibitor	Diabetic nephropathy	Europe Phase-II	Oral	In-house	
		Diabetic macular edema	US Phase-II			
ASP3662	11beta-HSD1 inhibitor	Painful diabetic peripheral neuropathy	US Phase-II	Oral	In-house	
		Alzheimer’s disease	US Phase-I			

(2) Phase-lll / Phase-ll (4/4)

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
CK-2127107	Fast skeletal tropoinin activator	Spinal muscular atrophy	US Phase-II	Oral	Cytokinetics	
		Chronic obstructive pulmonary disease	US Phase-II			
ASP7962	TrkA inhibitior	Osteoarthritis	Europe Phase-II	Oral	In-house	
AGS-16C3F	ADC targeting ENPP3	Renal cell carcinoma (ADC technology)	US/Europe Phase-II	Injection	In-house (ADC technology in-licensed from Seattle Genetics)	
RPE cell program	Cell therapy (Retinal pigment epithelium cell)	Dry age-related macular degeneration, Stargardt's macular degeneration	US Phase-II	Injection	In-house (Astellas Institute for Regenerative Medicine*)	

*Formerly known as Ocata Therapeutics

2. Local Development: Japan

(1) Approved

Code No. Generic Name	Product Name (Approval Date)	Classification	Target Disease	Area	Dosage Form	Licensor	Remarks
ASP1585 (AMG 223) bixalomer	Kiklin capsule (Feb. 2016)	Amine-functional polymer	Hyperphosphatemia in patients with chronic kidney disease*	Japan	Oral	Amgen	New indication

* Previous indication was hyperphosphatemia in patients on dialysis with chronic kidney disease.
The label was extended to include hyperphosphatemia in patients not receiving dialysis.

(2) Filed

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
ASP7374	Influenza vaccine	Prophylaxis of seasonal influenza	Japan Filed (May 2014)	Injection	UMN Pharma	
ASP1585 (AMG 223) bixalomer	Amine-functional polymer	Hyperphosphatemia in patients on dialysis with chronic kidney disease (granule formulation)	Japan Filed (Sept. 2015)	Oral	Amgen	New formulation
ASP0456 linaclotide	Guanylate cyclase-C receptor agonist	Irritable bowel syndrome with constipation	Japan Filed (Feb. 2016)	Oral	Ironwood	

(3) Phase-III / Phase-II

Code No. Generic Name	Classification	Target Disease	Area / Phase	Dosage Form	Licensor	Remarks
FK949E quetiapine	Serotonin / dopamine antagonist	Depressive episode in bipolar disorders	Japan Phase-III	Oral	AstraZeneca	New indication New formulation
ASP3550 degarelix	GnRH antagonist	Prostate cancer (three-month formulation)	Japan Phase-III	Injection	Ferring	New formulation
AMG 785 romosozumab	Anti-Sclerostin monoclonal antibody	Osteoporosis	Japan Phase-III	Injection	Amgen (co-development with Amgen Astellas)	
ipragliflozin/ sitagliptin	Fixed dose combination of ipragliflozin and sitagliptin	Type 2 diabetes mellitus	Japan Phase-III	Oral	In-house (co-development with MSD and Kotobuki)	
ASP0456 linaclotide	Guanylate cyclase-C receptor agonist	Chronic constipation	Japan Phase-II	Oral	Ironwood	New indication
ASP7373	Influenza vaccine	Prophylaxis of H5N1 influenza	Japan Phase-II	Injection	UMN Pharma	
ASP1941 ipragliflozin	SGLT2 inhibitor	Type 1 diabetes mellitus	Japan Phase-II	Oral	In-house (co-development with Kotobuki)	New indication

3. Phase-I

Code No. Generic Name	Target Disease	Dosage Form	Licensor
ASG-22ME	Cancer (ADC technology)	Injection	In-house (co-development with Seattle Genetics)
ASG-15ME	Cancer (ADC technology)	Injection	In-house (co-development with Seattle Genetics)
ASP5878	Cancer	Oral	In-house
AGS67E	Cancer (ADC technology)	Injection	In-house (ADC technology in-licensed from Seattle Genetics)
ASP2205	Stress urinary incontinence	Oral	In-house
ASP5094	Rheumatoid arthritis	Injection	In-house
AMG 103 blinatumomab	Acute lymphoblastic leukemia	Injection	Amgen (co-development with Amgen Astellas)
ASP4132	Cancer	Oral	In-house
ASP4345	Cognitive impairment associated with schizophrenia	Oral	In-house
ASP6282	Underactive bladder	Oral	In-house
ASP4070 (JRC2-LAMP-vax)	Pollinosis caused by Japanese red cedar	Injection	Immunomic Therapeutics
ASP0819	Fibromyalgia	Oral	In-house
ASP8062	Fibromyalgia	Oral	In-house
ASP7398	Nocturia	Oral	In-house
ASP6294	Bladder pain syndrome / Interstitial cystitis	Injection	In-house
ASP7266	Severe asthma	Injection	In-house

4. Discontinued

(1) Phase-I

Code No.	Target Disease
ASP6858	Chronic kidney disease

(2) Discontinued in a part of indication

Code No.	Target Disease	Area / Phase
ASP1707	Prostate cancer	Europe Phase-I

5. Other items changed from the previous quarterly announcement on January 29, 2016

-Removed the description of Repatha (evolocumab), which was launched in April 2016 in Japan.